Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0065)
Drug Name
Aliskiren
Synonyms
Aliskiren; Aliskiren fumarate; Aliskiren(CGP 60536); Enviage; Rasilez; Riprazo; SPP 100; SPP100; Sprimeo; Tekturna; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; 173334-57-1; 502FWN4Q32; CGP 60536; CGP60536B; CHEBI:601027; CHEMBL1639; UNII-502FWN4Q32
Indication Essential hypertension [ICD11: BA00] Approved [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 551.8 Topological Polar Surface Area 146
Heavy Atom Count 39 Rotatable Bond Count 19
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
5493444
PubChem SID
7980347 ; 14763777 ; 14886049 ; 17397362 ; 39475202 ; 46507474 ; 46509572 ; 51009124 ; 85176969 ; 87324641 ; 96099933 ; 103615727 ; 104178818 ; 114001043 ; 124897540 ; 126666078 ; 129435102 ; 134338459 ; 135916045 ; 137002989 ; 137227121 ; 140385193 ; 151991991 ; 152028160 ; 152258402 ; 160647239 ; 160964589 ; 162181387 ; 174006809 ; 175268617 ; 176485078 ; 177748803 ; 178101514 ; 179150066 ; 185997039 ; 187032771 ; 223393380 ; 223404348 ; 223435288 ; 223661693 ; 223720068 ; 224032552 ; 226775246 ; 242591596 ; 251916704 ; 251917943 ; 251970968 ; 252213891
ChEBI ID
CHEBI:601027
CAS Number
173334-57-1
TTD Drug ID
D03SVX
Formula
C30H53N3O6
Canonical SMILES
CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
InChI
1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
InChIKey
UXOWGYHJODZGMF-QORCZRPOSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Aliskiren metabolite M1 DM000042
15513344
Oxidation - O-Demethylation 1 [3]
Aliskiren metabolite M12 DM000044
9873303
Unclear 1 [4]
Aliskiren metabolite M3 DM000038
71315708
Oxidation - O-Demethylation 1 [3]
Aliskiren metabolite M4 DM000040
73603892
Oxidation - O-Dealkylation 1 [3]
Aliskiren metabolite M9 DM000043
11539359
Hydrolysis - Hydrolysis 1 [4]
Aliskiren metabolite M2 DM000039
71315706
Oxidation - Oxidation 2 [3]
Aliskiren metabolite M4 DM000040
73603892
Oxidation - O-Dealkylation 2 [3]
Aliskiren metabolite M6 DM000041
156028142
Conjugation - O-Glucuronidation 2 [3]
Aliskiren metabolite M4 DM000040
73603892
Oxidation - O-Dealkylation 3 [3]
Aliskiren metabolite M6 DM000041
156028142
Conjugation - O-Glucuronidation 3 [3]
Aliskiren metabolite M6 DM000041
156028142
Conjugation - O-Glucuronidation 4 [3]
⏷ Show the Full List of 11  DM(s)
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000132 Aliskiren Aliskiren metabolite M3 Oxidation - O-Demethylation Unclear [3]
MR000133 Aliskiren Aliskiren metabolite M4 Oxidation - O-Dealkylation CYP3A4 [3]
MR000134 Aliskiren Aliskiren metabolite M1 Oxidation - O-Demethylation CYP3A4 [3]
MR000135 Aliskiren Aliskiren metabolite M9 Hydrolysis - Hydrolysis Unclear [4]
MR000136 Aliskiren Aliskiren metabolite M12 Unclear Unclear [4]
MR000128 Aliskiren metabolite M3 Aliskiren metabolite M2 Oxidation - Oxidation Unclear [3]
MR000129 Aliskiren metabolite M3 Aliskiren metabolite M4 Oxidation - O-Dealkylation CYP3A4 [3]
MR000130 Aliskiren metabolite M2 Aliskiren metabolite M4 Oxidation - O-Dealkylation CYP3A4 [3]
MR000131 Aliskiren metabolite M4 Aliskiren metabolite M6 Conjugation - O-Glucuronidation Unclear [3]
⏷ Show the Full List of 9 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Aliskiren was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31.
3 Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers Drug Metab Dispos. 2007 Aug;35(8):1418-28. doi: 10.1124/dmd.106.013797.
4 U. S. FDA Label - Aliskiren

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.